Standing Order
All companies

Biotech

AstraZeneca PLC

AZNNASDAQdiversified
Market cap$270B
Conviction4/ 5
HQCambridge, UK
View full dashboard

For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.

Price · 1Y

$174.35

+138.8%

Thesis

AstraZeneca is a diversified large-cap pharma with one of the deepest oncology pipelines in the industry — Tagrisso in lung cancer, the Enhertu antibody-drug conjugate partnered with Daiichi Sankyo, and Imfinzi in immuno-oncology — alongside a major cardio-renal-metabolic franchise led by Farxiga. That breadth across oncology, CRM, respiratory, and rare disease (Alexion) gives unusually durable, broad-based growth.

The metabolic franchise and an emerging obesity / oral-GLP-1 program add a forward leg to a company already compounding. As a high-quality, well-positioned name, the key swings are pipeline-trial outcomes, the pace of its stated revenue-growth ambition, and exposure to China and drug-pricing policy.

Catalysts

  • Oncology pipeline readouts (Enhertu, Tagrisso, Imfinzi)
  • Cardio-renal-metabolic and obesity program progress
  • Revenue-growth ambition execution
  • China demand and pricing-policy developments

Recent events

Material filings, federal awards, and regulatory activity. Impact is scored against market cap.

  • Nov 16
    RegulatorySEC

    AstraZeneca's Klygefa (gefurulimab) approved in the EU.

  • Nov 16
    RegulatorySEC

    AstraZeneca's Imfinzi + EV approved in US for bladder cancer

  • Nov 16
    RegulatorySEC

    AstraZeneca's Klygefa (gefurulimab) approved in the US

  • Nov 16
    RegulatorySEC

    6-K: Baxfendy recommended for approval in the EU

  • Oct 30
    Financial resultsSEC

    AstraZeneca PLC files 6-K disclosing third quarter results.

  • Oct 27
    RegulatorySEC

    ENHERTU approved in EU for HER2-positive early breast cancer (EBC).

  • Oct 22
    RegulatorySEC

    Ultomiris approved in the US for IgA nephropathy per 6-K filing.

  • Oct 2
    PartnershipSEC

    AstraZeneca and Daiichi Sankyo collaboration with Summit for Datroway.

Not financial advice — research and opinion only. Disclosures